# Iain A. McNeish

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/iain-a-mcneish/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,316 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 72 |
| i10-index | 211 |
| Last Known Institution | Imperial College Healthcare NHS Trust |
| OpenAlex ID | https://openalex.org/A5089242165 |
| ORCID iD | https://orcid.org/0000-0002-9387-7586 |
| Works | 777 |

## Researcher papers

- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Rethinking ovarian cancer: recommendations for improving outcomes](https://scholariq.org/papers/rethinking-ovarian-cancer-recommendations-for-improving-outcomes/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk](https://scholariq.org/papers/common-genetic-variation-in-cellular-transport-genes-and-epithelial-ovarian/)
- [<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma](https://scholariq.org/papers/i-brca-i-reversion-mutations-in-circulating-tumor-dna-predict-primary-and/)
- [A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)](https://scholariq.org/papers/a-randomized-phase-iii-trial-to-evaluate-rucaparib-monotherapy-as-maintenance/)
- [ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease](https://scholariq.org/papers/esgo-esmo-esp-consensus-conference-recommendations-on-ovarian-cancer-pathology/)
- [Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2](https://scholariq.org/papers/antitumor-activity-and-safety-of-the-parp-inhibitor-rucaparib-in-patients-with/)
- [Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)](https://scholariq.org/papers/molecular-and-clinical-determinants-of-response-and-resistance-to-rucaparib-for/)
- [European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer](https://scholariq.org/papers/european-experts-consensus-brca-homologous-recombination-deficiency-testing-in/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research-2/)
- [CRISPR and Genetic Engineering](https://scholariq.org/topics/crispr-and-genetic-engineering/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Imperial College Healthcare NHS Trust](https://scholariq.org/institutions/imperial-college-healthcare-nhs-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.